Vancouver, BC Biotechnology and Pharmaceutical Companies directory and employer contacts list
The following Vancouver, BC, Canada Biotechnology and Pharmaceutical Companies are among the many key British Columbia organizations listed in the JobPro Directory.Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Lewis Choi, Ph.D., Vice President, Intellectual Properties and Scientific Affairs
Pacgen Biopharmaceuticals
Box 96, 1730 - 505 Burrard Street
Vancouver BC V7X 1M6
Tel. 604 436-4388
Fax. 604 436-4380
lchoid31vizo8l@pacgenbiopharm.com
infod31vizo8l@pacgenbiopharm.com
www.pacgenbiopharm.com
Dr. Choi has been Vice President, Intellectual Properties and Scientific Affairs since August 2009. Prior to his promotion, Dr. Choi served as Vice President, Research overseeing and managing all aspects of research and intellectual properties from April 2007 to August 2009. Prior to joining Pacgen, Dr. Choi acted as research and intellectual property consultant to various biopharmaceutical companies including Cardiome Pharma Corp. (“Cardiome"), Verona Pharma and Pacgen. Previous to this, Dr. Choi acted as Director of Intellectual Property to Cardiome. Dr. Choi also held various management and research positions in both the industry and academia settings including Inex Pharmaceuticals Corp. and the University of British Columbia. He also co-founded a contract research organization, Northern Lipids Inc.
Dr. Choi received his Ph.D. degree in Organic Chemistry and Bachelor of Science (Honours) degree in Chemistry from the University of London, United Kingdom. He is a co-inventor of over 30 issued patents and pending patent applications and a co-author of over 40 scientific publications and presentations.
Donna Shum, Global Product and Partnering Strategies
WEX Pharmaceuticals Inc.
1601 - 700 West Pender Street
Vancouver BC V6C 1G8
Tel. 604 683-8880
Fax. 604 683-8868
wexy7tgfi@wexpharma.com
www.wexpharma.com
November 11, 2008 - Donna Shum, former chief operating officer of Vancouver based Wex Pharmaceuticals, is reportedly now back at WEX as head of the team for global product and partnering strategies for TTX. Donna Shum brings a lot of experience to WEX and this should be seen as a very positive move for the company.
Perhaps no one understand TTX and the history of WEX more than Donna Shum, and this should complement CEO Huang in her mission to build WEX shareholder value. It is reported that CEO Huang may bring back one or two more former WEX employees that would be seen as very valuable additions to WEX.
Donna Shum was educated in both Hong Kong and Canada and obtained a Bachelor of Business Administration degree in Finance from Simon Fraser University in 1996. Ms. Shum is bilingual in English and Mandarin. She joined the Company at its Vancouver office in 1996 as controller and Corporate Secretary. Since 1996 she has acted as Chief Financial Officer with responsibility for the Company's dealings with its bankers, stock exchanges and auditors.
In 1997, she led the Company's capital reorganization and became a director. Since 1998, she has undertaken the raising of approximately $12.5 million in private placements for the Company. In 2000, Ms. Shum became Chief Operating Officer.
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageGabe Kalmar, Executive Director of Operations
Genome British Columbia / Genome BC
500 - 555 West 8th Avenue
Vancouver BC V5Z 1C6
Tel. 604 637-4374 - direct
Tel. 604 738-8072
Fax. 604 738-8597
gkalmarfh@genomebc.ca
infofh@genomebc.ca
www.genomebc.ca
For the past two years Dr. Kalmar has been engaged in strategic consulting activities with several early stage pharmaceutical companies which included overseeing operations, implementing technology development and providing merger and acquisition planning.
From 1996 to 2002 Dr. Kalmar held senior management positions with Kinetek Pharmaceuticals Inc., a privately held Vancouver-based biopharmaceutical company that was acquired by QLT in March, 2004. During this time Dr. Kalmar established and managed multiple external collaborations with academics and clinicians in the areas of signal transduction, preclinical studies and technology access.
Dr. Kalmar obtained his undergraduate science degree from the University of British Columbia and his Ph.D. in Biology from Simon Fraser University.
Dr. Michael Horne, Chief Scientific Officer
Functional Technologies Corp.
218 - 5511 West Boulevard
Vancouver BC V6M 4H3
Tel. 604 648-2200
Fax. 604 648-2201
info96fc@functionaltechcorp.com
www.functionaltechcorp.com
Michael Horne is an internationally regarded scientist who has led numerous scientific teams in the successful development and production of commercial human and animal healthcare products. Dr. Horne has demonstrated expertise in micro-organism product development in the commercial business sector. Most recently, he held the position of Director of Research in the animal health division of Novartis AG.
While at Novartis, he played a leading role in the expansion of the company's aquaculture franchise, including the development of the world's first commercialized, fully licensed DNA vaccine. He is the author of more than 100 technical, scientific and general publications, and participates on numerous international scientific committees.
As the company's chief scientific officer, Dr. Horne will devote himself full-time to leading and mentoring Functional Technologies' growing research and development team; supporting the commercial development and rollout of the company's proprietary Phyterra-branded yeast and micro algae-derived products; and expanding the company's product pipeline through the development of new and next-generation products and technologies identified as having commercial market applications in the functional foods and health products markets.
He will be based in the United Kingdom in order to provide the company with key visibility in the important European market, and to help facilitate Functional Technologies' future expansion into Europe.
Alexander Lussow, Vice President, Business Development
QLT Inc.
887 Great Northern Way
Vancouver, BC V5T 4T5
Tel. 604 707-7000
Fax. 604 707-7001
ir7ww@qltinc.com
www.qltinc.com
Alexander Lussow joined QLT in 2006 and is responsible for QLT's business development activities, including product licensing, acquisitions and strategic partnering opportunities.
Before joining QLT, Mr. Lussow was Gryphon Therapeutics' Chief Business Officer and Vice President of Business Development where he was responsible for the licensing of the company's products, the formation of strategic alliances, corporate communications and fund raising.
Before joining Gryphon, Alex served as the head of business development at Sangstat Medical Corporation (now wholly owned by Genzyme Corp.). He also has broad experience in biotechnology management consulting advising on venture financing, strategic business planning and licensing transactions for several biotechnology companies.
Mr. Lussow received his BSc at McGill University in Montreal and his PhD in immunology at the University of Geneva, Switzerland. He has been an adjunct professor of pharmacology at the University of North Carolina, USA and has worked extensively for the World Health Organization (WHO) in West Africa.
Allan Yap, Chairman and Chief Executive Officer
Burcon NutraScience Corporation
1946 West Broadway
Vancouver, BC V6J 1Z2
Tel. 604 733-0896
Fax. 604 733-8821
AYapcz03@burcon.ca
infocz03@burcon.ca
www.burcon.ca
Dr. Allan Yap, Burcon's Chairman and Chief Executive Officer, has over twenty-four years experience in finance, investment and banking, and is a former Chairman of the Oxford Properties Group Inc., whose international assets in the management and development of commercial and residential real estate exceed $3 billion.
Dr. Yap is the Chairman and Chief Executive Officer of China Enterprises Limited, an investment holding company active in the Peoples' Republic of China, whose shares are traded on the OTC Bulletin Board in the United States.
In addition to serving on the boards of several other public and private companies in North America, Dr. Yap is the Managing Director of Hanny Holdings Limited. The latter company, whose shares are listed on the Hong Kong Stock Exchange, was a co-owner of the Memorex® trademark until it was sold to Imation Corp. in April 2006.
Sweta Rajan, Research Associate
Boreal Genomics Inc.
302 - 2386 East Mall
Vancouver BC V6T1Z3
Tel. 604 822-8268
Fax. 604 822-4202
infotia@borealgenomics.com
www.borealgenomics.com
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageDr. Donald Wong, Vice President, Drug Development
Chemokine Therapeutics Corp.
400 - 1727 West Broadway
Vancouver, BC V6J 4S5
Tel. 604 738-6644
Fax. 604 738-6645
dwong8yf@chemokine.net
www.chemokine.net
Dr. Wong is an experienced researcher with 7 years of post doctoral and 5 years of doctoral experience in the fields of cytokines, growth factors, cardiovascular and neuropathological disorders.
He is the author of a number of important scientific publications on the role of the blood-brain barrier in multiple sclerosis, stroke and other inflammatory diseases in the brain, as well as the role of a leaky endothelium in atherosclerosis, especially in the context of diabetes and organ transplants.
He obtained his Ph.D. in Neuropathology at the University of British Columbia and carried out post-doctoral work at the laboratories of Dr. Steven Vincent and Dr. Bruce McManus. Dr. Wong has written over 20 scientific publications, and over 10 patents. He is responsible for conducting, and managing all the pre-clinical, drug development of Chemokine Therapeutics drugs.
Brian Nixon, President & Chief Executive Officer
Vizon SciTec Inc.
3650 Wesbrook Mall
Vancouver, BC V6S 2L2
Tel. 604 224-4331
Fax. 604 224-0540
info7@vizonscitec.com
www.vizonscitec.com
Mussawar Adeel,
Syreon Corporation
500 - 555 8th Avenue West
Vancouver, BC V5Z 1C6
Tel. 604 676-5900
Fax. 604 676-5911
Mussawar.Adeel0r@SYREON.COM
info0r@syreon.com
hr0r@syreon.com
www.syreon.com
Jacki Hatfield, Chief Executive Officer
Stemsoft Software Inc.
401 - 570 West 7th Avenue
Vancouver, BC V5Z 1B3
Tel. 604 668-0843 - direct
Tel. 604 877-0713
Fax. 604 877-0703 - direct
Fax. 604 877-0704
infom2@stemsoft.com
stemsoftm2@stemsoft.com
infowebm2@stemcell.com
www.stemsoft.com
www.stemcell.com
Jacki Hatfield is also Chief Executive Officer of StemCell Technologies Inc.
Becky Gillespie, Project Coordinator
Michael Smith Genome Sciences Centre / BC Cancer Research Centre
675 West 10th Avenue
Vancouver BC V5Z 1L3
Tel. 604 707-5900 X 5413 - direct
Tel. 604 675-8150
Fax. 604 675-8178
bgillespiekxy5k@bcgsc.ca
infokxy5k@bcgsc.bc.ca
www.bcgsc.ca
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageRandy Willardsen, M.Sc., Senior Vice President, Process
Burcon NutraScience Corporation
1946 West Broadway
Vancouver, BC V6J 1Z2
Tel. 604 733-0896
Fax. 604 733-8821
RWillardsenskol@burcon.ca
infoskol@burcon.ca
www.burcon.ca
Mr. Willardsen has earned a reputation as a leader in the development and application of protein isolation technologies, with several of his innovations gaining widespread use throughout the food industry, including a unique microfiltration system for the production of whey protein isolates.
Mr. Willardsen holds a master's degree in food science and nutrition from the University of Minnesota and has over twenty years' experience in the fields of membrane filtration and food, dairy and biotechnology processes.
As senior VP, process, Mr. Willardsen is responsible for process development at the Burcon Technical Centre in Winnipeg. He leads the process engineering team's efforts as they continue research and development of Burcon's protein extraction and purification technology, and carry out process enhancements, with a view to commercializing Puratein® while also broadening the application of the company's patented extraction process to other oilseed sources.
Duane Morris, Chief Operating Officer
Response Biomedical Corporation
1781 West 75 Avenue
Vancouver, BC V6P 6P2
Tel. 604 456-6010
Fax. 604 456-6066
DMorris1rijc2@responsebio.com
www.responsebio.com
Mr. Morris joins Response Biomedical from GlaxoSmithKline (GSK), where he was Vice President and General Manager of GSK's Bothell, Washington, Biodefense facility. Prior to that, Mr. Morris was Vice President of Operations at ID Biomedical, responsible for all North American Operations.
Before joining ID Biomedical, Mr. Morris was Vice President of Operations for Cypress Bioscience. He has also held a variety of senior positions at Syntex Laboratories, and became Director of Manufacturing for Syntex's Palo Alto Operations in 1993.
Dr. Surjit Dixit Ph.D., Chief Technology Officer
Zymeworks Inc.
540 - 1385 West 8th Avenue
Vancouver BC V6H 3V9
Tel. 604 678-1388
Fax. 604 737-7077
infoehq@zymeworks.com
www.zymeworks.com
Dr. Dixit is Zymeworks' Chief Technology Officer, responsible for the implementation of novel algorithms and advancement of the ZymeCAD™ platform. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Weselyan University, Connecticut, USA, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data.
Dr. Dixit obtained his PhD at the Indian Institute of Technology, New Delhi researching methods for computing the binding and interaction energies in protein DNA complexes. Subsequently he was a post doctoral research associate at the Université Henri Poincaré, Nancy, France, working on the development and implementation of highly accurate methods for the prediction of binding energies in drug discovery research.
Jay Fei, Network Manager, BCCRC IT and Web Coordinator, BCCRC Web Committee
BC Cancer Research Centre (div. of BC Cancer Agency)
675 West 10th Avenue
Vancouver, BC V5Z 1L3
Tel. 604 675-8000
Fax.
jfeinys@bccrc.ca
www.bccrc.ca
Jay Fei spends 80% of his work time designing, building, and maintaining the BCCRC network including network infrastructure, e-mail, and firewall. The other 20% is to keep this website up and running, and response to any web related questions and comments.
Pieter Cullis, Ph.D, FRSC, Scientific Director
UBC Centre for Drug Research and Development
Professor, Department of Biochemistry and Molecular Biology, Life Sciences Centre, UBC
364 - 2259 Lower Mall
Vancouver, BC V6T 1Z4
Tel. 604 221-7750 X 105 - direct
Tel. 604 221-7750
Fax. 604 221-7753
pieterc2kya7c0f@interchange.ubc.ca
info2kya7c0f@cdrd.ca
www.cdrd.ca
Dr. Cullis is a Professor in the Department of Biochemistry and Molecular Biology, UBC, and Chief Scientific Officer and Senior Vice President, Research, at Inex Pharmaceuticals Corporation. His laboratory is focused on the development of liposomal systems for delivery of conventional and genetic drugs.
This work has led to two products that have been approved by regulatory agencies for the treatment of cancer and its complications. Dr. Cullis has published over 250 scientific articles and is an inventor on over 30 patents.
Dr. Cullis was awarded the B.C. Science Council Gold Medal for Health Sciences in 1991, the international Alec D. Bangham Award in 2000 and the B.C. Biotechnology Association Award for Innovation and Achievement in 2002. He was elected to the Royal Society of Canada in 2004.
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageNatalie Dakers, Founder and Chief Executive Officer
UBC Centre for Drug Research and Development
364 - 2259 Lower Mall
Vancouver, BC V6T 1Z4
Tel. 604 221-7750 X 102 - direct
Tel. 604 221-7750
Fax. 604 221-7753
ndakersns6@cdrd.ca
infons6@cdrd.ca
www.cdrd.ca
Ms. Dakers was President & CEO of Neuromed Technologies Inc., a private biopharmaceutical company developing drugs for chronic pain, anxiety, epilepsy and cardiovascular diseases.
As co-founder, she built the company from inception and raised three rounds of venture financing totaling approximately $70 million. Under her leadership, the company filed its first Investigational New Drug (IND) application for a novel chronic pain drug and commenced Phase 1 clinical trials.
Prior to co-founding Neuromed, Ms. Dakers was a Senior Manager for life sciences technology transfer at the University Industry Liaison Office (UILO) at the University of British Columbia. In this capacity, she was involved in the creation and spin-off of more than a dozen start-up high-tech and biotech companies.
Ms. Dakers served as Chair of BC Biotech, the association representing and promoting the province's biotech firms. From 1999 to 2001, she served as a board member of AceTech Academy of Technology CEOs. Ms. Dakers has also served as Vice-President of the Association of University Technology Managers and as Director of the Premier's Advisory Council of Science and Technology.
After graduating from University of Guelph with an honours degree in marine biology, Dakers worked as a research biologist for a B.C. salmon aquaculture company. In 1989, she joined UBC's University-Industry Liaison Office (UILO) where, as senior manager for life sciences technology transfer, she learned about venture financing, licensing agreements and the complex world of commercialization.
I was lucky enough to work with creative people in an office that was leading the way in tech transfer in Canada, says Dakers.
She acknowledges that there are strong and polarized feelings on commercialization -- some believe it doesn't fit with the research and education mandate of a university.
If you do it right, you can enhance a university's reputation, she says. A spin-off is the vehicle to enable discovery.
After eight years and helping to create more than a dozen spin-offs, Dakers decided she had done enough facilitating and wanted to get in the game.
She had worked with UBC neurobiologist Terry Snutch on some research contracts and was impressed with his stellar science. He has developed compounds to block calcium channels in the brain that transmit pain signals. The drugs are aimed at patients with chronic pain and other severe neurological disorders, such as epilepsy.
The pair -- with no formal business training between them -- launched Neuromed Technologies Inc. in 1998 to commercialize Snutch's ideas in developing pain-killing drugs.
Early on I could have simply licensed out the technology and walked away, says Snutch. It's been a very long road but the experience has been worth all the effort - there hasn't been a dull moment. And although there's still a long way to go, we based Neuromed on solid scientific rationale and never wavered from the original concept of drug development as the best way to create and maintain value.
I jumped in and never looked back, says Dakers. We were passionate about what we were doing. We never lost faith.
But their faith was tested. In January 2002, the first compound failed at a critical point in the financing process. It was one of the sickening plummets in what Dakers calls the roller-coaster ride of running a spin-off. She spent a year getting investors excited once again about the venture and the second compound they were set to try.
By January 2003, she had raised a total of $70 million for Neuromed, which propelled it toward what she describes as her proudest moment -- when the first clinical trial participants received doses of calcium channel blockers.
But with that success came a very difficult decision. In October 2003, Neuromed had secured the third round of financing. The agreement with lead investor, MPM Capital, meant the company would have a new CEO operating from the U.S. Dakers had to let go of Neuromed, although the research base remains in Vancouver and Snutch continues as vice-president and chief scientific officer.
Rui Avelar, MD, CCFP, DIP SPORT MED, Chief Medical Officer
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver BC V6A 1B6
Tel. 604 221-7676
Fax. 604 221-2330
infozqd53@angio.com
RAvelarzqd53@angio.com
www.angiotech.com
Dr. Rui Avelar is Angiotech's Chief Medical Officer and is responsible for medical market analysis, product concept, development and clinical trial design. Dr. Avelar brings to the company over a decade of clinical experience from his previous medical practice where he specialized in Sports Medicine. He also brings knowledge of the pharmaceutical industry and markets from a previously held position as a healthcare analyst for a Canadian securities firm prior to joining Angiotech. Dr. Avelar remains active as the team physician for the NHL franchise team, the Vancouver Canucks.
Dr. Avelar received his medical degree from the University of Toronto in 1989 and went on to further training and accreditation in Sports Medicine receiving his certification from the Canadian Academy of Sports Medicine.
Dr. Richard Bastiani, Chairman
Response Biomedical Corporation
1781 West 75 Avenue
Vancouver, BC V6P 6P2
Tel. 604 456-6010
Fax. 604 456-6066
www.responsebio.com
Dr. Richard Bastiani, former Chairman of ID Biomedical, has an impressive track record in the life sciences industry with considerable operational expertise in developing and commercializing innovative technology, and building successful businesses.
Dr. Bastiani has served on the board of Abaxis Inc, which specializes in point-of-care diagnostics, since September 1995. He is a director and co-founder of DiscoverRx, which is focused on high-throughput screening and proteomics products for pharmaceutical drug discovery.
Previously, Dr. Bastiani was President of Dendreon, a biotechnology company developing cell-based therapies for treatment of cancer, until September 1999. For approximately 25 years, Dr. Bastiani held a number of positions, including President, of Syva Company in Palo Alto, California.
Amanda Fuller, B.Sc., Clinical Logistics Coordinator
BRI Biopharmaceutical Research Inc.
101 - 8898 Heather Street
Vancouver, BC V6P 3S8
Tel. 604 432-9237
Fax. 604 432-9239
AFullerqa@bripharm.com
infoqa@bripharm.com
www.bripharm.com
After joining BRI in September 2002, Ms. Fuller began her role in the coordination of an ongoing Therapeutic Drug Monitoring (TDM) program involving an ongoing LC/MS/MS screening and quantitation of protease inhibitors in bio-hazardous clinical samples from across Canada. Also serving as the Biological Safety Officer for BRI, Ms. Fuller has a broad scope of knowledge and experience in coordinating the collection and shipment of all types of biological samples from worldwide international locations for importation to Canada.
This includes working with clinical sites to provide sample collection and shipping kits and providing documentation support for shipments across international borders. Amanda also manages raw material inventory and logistics relating to BRI's role in outsourcing and managing cGMP manufacturing of APIs and clinical products, including packaging and distribution of clinical finished products to clinical sites.
Amanda Smith, Corporate Communications (via Smith Biotech)
ARC Pharmaceuticals Inc.
102 - 2386 East Mall
Vancouver, BC V6T 1Z3
Tel. 778 846-4116 - cell
Tel. 604 222-9577
Fax. 604 222-9578
amandaj9p@smithbiotech.com
infoj9p@arcpharma.com
www.arcpharma.com
Amanda Smith runs Smith Biotech (in this directory).
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageAndreas Rose, Vice President, Engineering
Ondine Biopharma Corporation
910 - 1100 Melville Street
Vancouver, BC V6E 4A6
Tel. 604 669-0555
Fax. 604 669-0533
ARoseb@ondinebiopharma.com
infob@ondinebiopharma.com
www.ondinebiopharma.com
Andreas holds a "Diplom-Ingenieur" degree from University of Applied Sciences in Giessen, Germany. He has gained his considerable expertise as Head of R&D, VP Engineering, and Consultant in Europe, the US and Japan for several market leaders in the field of fiber optics, laser display, and laser technology.
Mr. Rose is well known as an expert in the scientific and industrial field of fiber optics and lasers. He is Short Course Instructor for "Packaging of Optoelectronic Components" at the reputable conference in this field, the "Conference on Lasers and Electro Optics (CLEO).
Jacki Hatfield, Chief Executive Officer
Stemsoft Software Inc.
400 - 570 West 7th Avenue
Vancouver, BC V5Z 1B3
Tel. 604 668-0843 - direct
Tel. 604 877-0713
Fax. 604 877-0703 - direct
Fax. 604 877-0704
infoxh5@stemsoft.com
stemsoftxh5@stemsoft.com
infowebxh5@stemcell.com
www.stemsoft.com
www.stemcell.com
John Parkinson, Chief Financial Officer
Protox Therapeutics Inc.
1210 - 885 West Georgia Street
Vancouver BC V6C 3E8
Tel. 604 688-0199
Fax. 604 688-0173
JParkinsonhpn97@protoxtherapeutics.com
infohpn97@protoxtherapeutics.com
www.protoxtherapeutics.com
March 23, 2009 - Protox Therapeutics Inc. announced that John Parkinson has been appointed Chief Financial Officer of the Company, effective immediately. Mr. Parkinson will replace David Swetlow, Vice President of Finance and Operations, who is leaving Protox to pursue entrepreneurial opportunities.
"John has proven leadership capabilities, business acumen and a track record of successfully managing change and delivering profitable growth," said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. "His wealth of knowledge and experience in the US and Canadian capital markets, managing sizable partnership relationships, as well as his thorough understanding of business operations, will provide tremendous depth to our management team.
John will play an essential role as we continue to advance our business development strategies and broaden and strengthen our relationships with the financial community. He also will be able to work from the foundation built by David during his time with us, who we wish every success in his new endeavor."
Mr. Parkinson has cross-industry experience in the management of high growth, dynamic global companies. Previously, he was Vice President, Finance at Aspreva Pharmaceuticals, a rapidly growing public company formed in 2003 and recently sold to a diversified European healthcare group for over $1 billion. He was a key factor in Aspreva's TSX and NASDAQ $100 million IPO in 2005, the largest in Canadian healthcare history.
Mr. Parkinson co-chaired the Joint Finance Committee with partner Hoffman-La Roche, which held the responsibility for managing the financial elements of their $1.7 billion annual revenue sharing and collaboration agreement. Previously, he focused on financial, high-tech and public company practices during his 10 years with KPMG. He is a member of the Audit and Finance Committee of VIATeC, (the Vancouver Island Advanced Technology Society) and the Institute of Chartered Accountants of British Columbia.
Mr. Parkinson is a graduate of the University of Saskatchewan where he received a Bachelor of Commerce and Bachelor of Arts in Economics.
Anthony Boone, Director, Corporate Communications
Protox Therapeutics Inc.
1210 - 885 West Georgia Street
Vancouver, BC V6C 3E8
Tel. 604 688-0199
Tel. 778 996-4369 - cell
Fax. 604 688-0173
aboone1xk4@protoxtherapeutics.com
info1xk4@protoxtherapeutics.com
www.protoxtherapeutics.com
Gordon McCauley, President and Chief Executive Officer
Allon Therapeutics Inc.
506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Tel. 604 742-2540 - direct
Tel. 604 736-0634
Fax. 604 736-1616
gmccauley997sl@allontherapeutics.com
info997sl@allontherapeutics.com
www.allontherapeutics.com
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageShumsheer Sidhu, Manager of Finance
PrioNet Canada
200 - 2386 East Mall
Vancouver BC V6T 1Z3
Tel. 604 222-3607 - direct
Tel. 604 222-3600
Fax. 604 222-3606
ssidu3nk@prionetcanada.ca
admin3nk@prionetcanada.ca
www.prionetcanada.ca
Shumsheer joined PrioNet in October 2009. Shumsheer successfully completed the Certified Management Accounting (CMA) Accelerated Program and is working towards her CMA designation. Prior to her career in finance, Shumsheer ran the successful Canadian Bioinformatics Workshops through the Canadian Genetic Diseases Network. She also worked as an outreach coordinator for the Canadian Gene Cure Foundation for the “Jeans for Genes Day Campaign".
Shumsheer is responsible for all of PrioNet's financial processing, assistance in the preparation of financial statements, budgeting and internal and external audits.
Dr. Andrew Janoff, Ph.D., Chief Executive Officer and Chairman
Celator Pharmaceuticals Corp.
1779 West 75th Avenue
Vancouver, BC V6P 6P2
Tel. 604 708-5858
Fax. 604 708-5883
AJanoffxg@celatorpharma.com
infoxg@celatorpharma.com
www.celatorpharma.com
Carolyn Cross, Founder and Chief Executive Officer
Ondine Biopharma Corporation
910 - 1100 Melville Street
Vancouver, BC V6E 4A6
Tel. 604 669-0555
Fax. 604 669-0533
ccross9d3d688@ondinebiopharma.com
info9d3d688@ondinebiopharma.com
www.ondinebiopharma.com
Cross is a founder of Ondine Biopharma, having been with the company since 1999. Prior to Ondine, Mrs. Cross was involved with several other start ups directly and indirectly through Vencourt Capital, a venture capital company located in Vancouver that provides capital, management expertise and technology to early stage companies.
As a former Vice President with Royal Bank Investment Management Inc., the fund management arm of the Royal Bank of Canada, with the responsibilities of managing pension, pooled, mutual and private client funds, Mrs. Cross brings an institutional investor approach to the management of Ondine.
She holds a CFA designation, an MBA from York University and an HB from University of Western Ontario.
Jacqueline Tiong, Director, Corporate Development
Allon Therapeutics Inc.
506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Tel. 604 736-0634
Fax. 604 736-1616
jtiongo65@allontherapeutics.com
infoo65@allontherapeutics.com
www.allontherapeutics.com
Dr. William Hunter, President and CEO
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver, BC V6A 1B6
Tel. 604 221-7676
Fax. 604 221-2330
WHunter5dgp7quh@angio.com
www.angiotech.com
Hunter has been the cornerstone of Angiotech's dramatic growth as a world leader in the innovative field of utilizing drugs to enhance the performance of medical devices and biomaterials. After Angiotech's inception, Dr. Hunter took his position as a Company founder and Chief Scientific Officer and built a nucleus of management whose scientific and strategic expertise has led to increasing shareholder value and a robust product pipeline.
This pipeline includes the most successfully launched product in medical history-the TAXUS® paclitaxel-eluting coronary stent, implanted in over a million patients worldwide.
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageAlain Curaudeau, Senior Vice President, Portfolio and Project Management
QLT Inc.
887 Great Northern Way
Vancouver, BC V5T 4T5
Tel. 604 707-7000
Fax. 604 707-7001
irm50bpkss@qltinc.com
www.qltinc.com
Mr. Curaudeau comes to QLT with extensive global experience in pharmaceutical research and development after serving more than 15 years with Rhone-Poulenc Rorer (RPR), a major international pharmaceutical company. His tenure with RPR included 14 years of progressively senior positions in project management, in France and in the U.S. Most recently he was designated head of Project Management for Aventis, a new company formed in 1999 by the merger between RPR and Hoechst AG.
Mr. Curaudeau holds a Pharm.D from the University of Chatenay-Malabry, Paris, France. He is also a graduate of the Toxicology and Pharmacokinetics Programs from the same university and received academic training in toxicological pathology from the National Veterinary School in Toulouse, France.
Tessa Strong, Business Development
StemCell Technologies Inc.
400 - 570 West 7th Avenue
Vancouver, BC V5Z 1B3
Tel. 604 877-0713
Fax. 604 877-0704
tessaav611@stemcell.com
infowebav611@stemcell.com
www.stemcell.com
Su Lee, Executive Assistant
UBC Centre for Drug Research and Development
364 - 2259 Lower Mall
Vancouver, BC V6T 1Z4
Tel. 604 221-7750 X 103 - direct
Tel. 604 221-7750
Fax. 604 221-7753
slee9msl@cdrd.ca
info9msl@cdrd.ca
www.cdrd.ca
Dr. Allen Eaves, President
StemCell Technologies Inc.
400 - 570 West 7th Avenue
Vancouver, BC V5Z 1B3
Tel. 604 668-0854
Tel. 800 667-0322
Fax. 604 877-0704
allenl1@stemcell.com
infowebl1@stemcell.com
stemsoftl1@stemsoft.com
www.stemsoft.com
www.stemcell.com
Christopher Gallen, M.D., Ph.D., President and Chief Executive Officer
Neuromed Pharmaceuticals Ltd.
301 - 2389 Health Sciences Mall
Vancouver, BC V6T 1Z4
Tel. 604 909-2530
Fax. 604 909-2538
cgalleny@neuromed.com
infoy@neuromedtech.com
www.neuromedtech.com
Dr. Gallen joined Neuromed in July 2004 as President & CEO and has led the company to two of its private equity financings, a transformative licensing deal with Merck & Co. and an acquisition of the U.S. marketing rights of a Phase 3 chronic pain product from ALZA Corporation.
Dr. Gallen has extensive experience in clinical and corporate development and has been instrumental in the commercialization of several drugs. Most recently, Dr. Gallen was Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training and was a key driver in the re-engineering of Wyeth Clinical Research and Development.
Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere. Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation.
Dr. Gallen received his M.D. and Ph.D. (Biochemistry) from the Emory University School of Medicine in Atlanta, Georgia and completed residencies in Psychiatry at Stanford and in Neurology at UCSD.
Find better employment faster with the JobPro British Columbia Employers Directory, and get connected to the industries, companies and the people running them of greatest value to you. Try JobPro today for free for more contacts and detailed company information from this and over 80 other industries across British Columbia.
Add or update company & contact information, or send feedback to directory maintainers.
Top of pageAmanda Smith, B.Sc., Founder and Creative Director
Smith Biotech
3432 West 13th Avenue
Vancouver, BC V6R 2S1
Tel. 778 846-4116
Fax. 604 608-6337
amandas9u@smithbiotech.com
inquiriess9u@smithbiotech.com
www.smithbiotech.com
Amanda is the Founder and Creative Director for Smith Biotech. She obtained a BSc. in Biology from Acadia University and possesses a diverse background in scientific, marketing and business development initiatives. Her passion for science and experience in assisting companies promote their research programs resulted in the establishment of Smith Biotech.
Amanda's goal with Smith Biotech is to not only provide traditional marketing products but to also encourage dialogue between industry professionals, researchers, partners, investors and consumers in order to foster continued growth within the industry.
Amanda is also actively involved in the promotion of the science & technology industry. Amanda is currently the Vice President of the Wired Woman Society, the Vice President Programming of the Society for Women in Science & Technology and she sits on the board of directors for the Science Fair Foundation of BC. She is a telementor and speaker for various events encouraging young people to pursue careers in technology.
Chris Dennis, Senior Vice President, Sales and Marketing
Angiotech Pharmaceuticals Inc.
1618 Station Street
Vancouver, BC V6A 1B6
Tel. 604 221-7676
Fax. 604 221-2330
CDennisbzqrifw@angio.com
infobzqrifw@angio.com
www.angiotech.com
April 3, 2007
Angiotech Appoints Chris Dennis as Senior Vice President, Sales and Marketing
Mr. Dennis brings to Angiotech a broad background in marketing, sales and general management in the health care sector including over 17 years of experience working for various subsidiaries of Johnson & Johnson (J&J).
Prior to joining Angiotech, Mr. Dennis was Global President of J&J's OrthoNeutrogena company (pharmaceuticals and aesthetic devices), where he was responsible for overall strategy and business growth initiatives.
Previously, he held the position of Vice President, Marketing & Sales for Janssen Ortho, Inc. (pharmaceuticals), where he managed the sales and marketing of a wide range of prescription medications.
Mr. Dennis also held the position of President, LifeScan Canada Ltd. (medical devices), where he oversaw the sales, marketing and distribution of diagnostic products for people with diabetes. He also held a number of sales and management roles at McNeil Consumer Products, a J&J company, and Bristol Myers Products Canada.
"This time last year, Angiotech was a company with significant expertise in R&D and a substantial intellectual property portfolio. Today, we have built on that foundation and grown to become a fully integrated and commercialized specialty pharmaceutical and medical device company.
With our comprehensive manufacturing, sales and marketing capabilities, we're pleased that Angiotech is attracting industry leaders like Chris to our senior management team," said Dr. William Hunter, President and CEO of Angiotech.
As Senior Vice President, Sales and Marketing, Mr. Dennis will be focused on building a global sales and marketing organization with a commercialization strategy that includes Angiotech's five identified focus markets. Angiotech anticipates a number of important product launches in 2007, including the Quill(R) SRS wound closure system and Angiotech's anti-infective 5-FU CVC.
S. Wayne Kay, Chief Executive Officer and Member, Board of Directors
Response Biomedical Corporation
1781 West 75 Avenue
Vancouver, BC V6P 6P2
Tel. 604 456-6010
Fax. 604 456-6066
SKaylqssm27@responsebio.com
www.responsebio.com
September 12, 2007 - Response Biomedical today announced the appointment of S. Wayne Kay as Chief Executive Officer and to the Company's Board of Directors.
Mr. Kay is a former President, CEO and Director of Quidel Corporation, a leading global company in the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care (POC) in infectious diseases and reproductive health.
During his tenure he designed and managed a strategy responsible for building and sustaining unprecedented market leadership of rapid influenza testing (from an approximately 2 percent to 49 percent market share).
He was also responsible for significantly improving the financial performance of the company during his tenure. Since leaving Quidel in 2004, Mr. Kay served as an executive advisor to the management and boards of several early stage companies, mainly in the San Francisco and San Diego areas.
He also served as an executive advisor to one of the US's most successful blue-chip healthcare/life sciences venture capital funds, Kleiner Perkins Caufield and Byers.
"I am very pleased to be joining Response Biomedical at this exciting time in the evolution of the Company," said Mr. Kay. "With partnerships in place with Shionogi & Co. Ltd. and 3M Company, we are poised for strong growth.
I look forward to leading the execution of our cardiovascular partnering strategy, as well as the scale-up in manufacturing, the launch of the new RAMP(R) Reader and the regulatory approval of three products, all anticipated in the next few quarters. These are the building blocks which I believe will significantly enhance shareholder value."
